Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Compositional changes within the normal intestinal microbiota have been associated with the development of various intestinal inflammatory disorders such as pouchitis and inflammatory bowel diseases (IBD). Therefore, it has been speculated that manipulation of a dysbiotic intestinal microbiota has the potential to restore microbial homeostasis and attenuate inflammation. METHODS: We performed community composition analyses by terminal restriction fragment length polymorphism (T-RFLP) of the bacterial 16S ribosomal RNA gene to investigate the impact of the probiotic VSL#3 on colonic microbial community composition and development of trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. RESULTS: TNBS-induced chronic colitis was significantly reduced in VSL#3-fed rats compared to controls (P < 0.05). T-RFLP analysis revealed distinct microbial communities at luminal versus mucosal sites. Within the luminal microbiota, chronic colitis was associated with an overall decrease in bacterial richness and diversity (Margalef's richness, P < 0.01; Shannon diversity, P < 0.01). This decrease in luminal microbial diversity was enhanced in TNBS-treated rats fed VSL#3 (Margalef's richness, P < 0.001; Shannon diversity, P < 0.001) and significantly correlated with reduced clinical colitis scores (Pearson correlation P < 0.05). CONCLUSIONS: Our data demonstrate that the probiotic VSL#3 alters the composition of the intestinal microbiota and these changes correlate with VSL#3-induced disease protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Bacterial Community Variation in Human Body Habitats Across Space and Time
Costello, E. K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J. I., & Knight, R. (2009) · Science · doi:10.1126/science.1177486 · Cited by 3,231 · cited 1×
“Luminal and Mucosally Adherent Microbiota Display Distinct Microbial Community Signatures Microbial communities have been shown to differ in composition across different anatomical sites in humans.(27,28) Accordingly, we employed community fingerprinting by T-RFLP to evaluate the microbiota of TNBS-treated rats within…”
BackgroundReduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · cited 1×
“This finding is consistent with recent work by Dore and coworkers who used a metagenomic approach to demonstrate that the diversity of the fecal microbiota in Crohn's patients is markedly reduced compared to that in healthy controls (31).”
ResultCorr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C., & Gahan, C. G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700440104 · Cited by 853
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513 · cited 1×
“DISCUSSION There is a growing body of evidence suggesting that probiotic consumption promotes gastrointestinal health, representing a new avenue for the treatment of diseases such as pouchitis and IBD.(29,30) Understanding how these healthful effects are conferred will allow for more rational design of probiotic mixtu…”
BackgroundProbiotics promote gut health through stimulation of epithelial innate immunity
Pagnini, C., Saeed, R., Bamias, G., Arseneau, K. O., Pizarro, T. T., & Cominelli, F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910307107 · Cited by 358 · cited 4×
“thermophilus, the concentration of which is highest among the components of VSL#3 and is maintained at high levels in the intestine after consumption.(12) We found a 64- and 36-fold increase in S.”
BackgroundResultInfluentialOkamoto, T., Sasaki, M., Tsujikawa, T., Fujiyama, Y., Bamba, T., & Kusunoki, M. (2000) · Journal of Gastroenterology · doi:10.1007/s005350050358 · Cited by 91 · cited 1×
“While the mechanism underlying the therapeutic effect of VSL#3 is currently unknown, it has been speculated that the beneficial activities of probiotics are propagated through a wide range of effects including inhibition of bacterial translocation, release of bacteriocidin and lactic acid, production of butyric acid,…”
Background
Cited by
Intestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
The pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398
Inflammation and colorectal cancer: colitis-associated neoplasia
Grivennikov, S. I. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0352-6 · Cited by 551
Probiotics, Prebiotics and Immunomodulation of Gut Mucosal Defences: Homeostasis and Immunopathology
Hardy, H., Harris, J., Lyon, E., Beal, J., & Foey, A. (2013) · Nutrients · doi:10.3390/nu5061869 · Cited by 546
Turroni, F., Ventura, M., Buttó, L. F., Duranti, S., O’Toole, P. W., Motherway, M. O., & van Sinderen, D. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1318-0 · Cited by 336
“1 3 scores in IL10-deficient mice [70], to suppress ileitis [71] and colitis [72] in murine models, to prevent colorectal cancer in a DSS-mice model [73], and to ameliorate liver dysfunction [74].”
BackgroundZhang, H.-L., Yu, L.-X., Yang, W., Tang, L., Lin, Y., Wu, H., Zhai, B., Tan, Y.-X., Shan, L., Liu, Q., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.011 · Cited by 281
“Probiotics are known to beneficially affect their hosts by improving the intestinal microbial balance and inhibiting the release of pathogens and toxin from bacteria [21].”
BackgroundThe Role of Probiotics and Prebiotics in Inducing Gut Immunity
Vieira, A. T., Teixeira, M. M., & Martins, F. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00445 · Cited by 273
Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.005 · Cited by 266
Dog and human inflammatory bowel disease rely on overlapping yet distinct dysbiosis networks
Vázquez-Baeza, Y., Hyde, E. R., Suchodolski, J. S., & Knight, R. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.177 · Cited by 261
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) · Drugs · doi:10.2165/11632710-000000000-00000 · Cited by 240
Yoo, S., Kim, Y., Park, D., Jung, U., Jeon, S., Ahn, Y., Huh, C., McGregor, R., & Choi, M. S. (2013) · Obesity · doi:10.1002/oby.20428 · Cited by 230
Arthur, J. C., Gharaibeh, R. Z., Uronis, J. M., Perez-Chanona, E., Sha, W., Tomkovich, S., Mühlbauer, M., Fodor, A. A., & Jobin, C. (2013) · Scientific Reports · doi:10.1038/srep02868 · Cited by 118
Self-citation
Metadata
- Authors
- Uronis, J. M., Arthur, J. C., Keku, T., Fodor, A., Carroll, I. M., Cruz, M. L., Appleyard, C. B., & Jobin, C.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01
- Volume
- 17
- Issue
- 1
- Pages
- 289-297
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W1985462428
- Cited by
- 105
- References
- 7
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.